GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
Ms. Katherine Stueland is the Chief Executive Officer of GeneDx Holdings Corp, joining the firm since 2022.
What is the price performance of WGS stock?
The current price of WGS is $56.26, it has increased 6.11% in the last trading day.
What are the primary business themes or industries for GeneDx Holdings Corp?
GeneDx Holdings Corp belongs to Health Care industry and the sector is Health Care
What is GeneDx Holdings Corp market cap?
GeneDx Holdings Corp's current market cap is $1.6B
Is GeneDx Holdings Corp a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for GeneDx Holdings Corp, including 4 strong buy, 5 buy, 2 hold, 0 sell, and 4 strong sell